Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis? - Poll - MDSpire

Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

  • By

  • Marcel Alexander Drews

  • Alexander Baumgarten

  • Sebastian Zensen

  • Marcel Opitz

  • Denise Bos

  • Lisa Zimmer

  • Selma Ugurel

  • Johannes Haubold

  • Dirk Schadendorf

  • Elisabeth Livingstone

  • Benedikt M. Schaarschmidt

  • May 1, 2025

  • 0 min

Share

Original Source(s)

Adverse effects of systemic advanced melanoma therapies—do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

  • by Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, Marcel Opitz, Denise Bos, Lisa Zimmer, Selma Ugurel, Johannes Haubold, Dirk Schadendorf, Elisabeth Livingstone, Benedikt M. Schaarschmidt

  • May 1, 2025

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery

Absolute risk of developing a second primary cancer after a first primary melanoma: an Australian population-based cohort study